{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-07T03:22:55.630971+00:00","company":{"ticker":"LEXX","cik":1348362,"company_name":"Lexaria Bioscience Corp."},"pagination":{"limit":100,"returned":14,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"exchange_compliance_notice","fact_key":"9ef70abe50e7421cee1cdcbaeb81371206e9ae25","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2026-02-06T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-02-06","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Lexaria Bioscience Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-26-000230","anchor_url":"https://secwatch.observer/filing/0001640334-26-000230#claim-9ef70abe50e7421cee1cdcbaeb81371206e9ae25","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033426000230/0001640334-26-000230-index.htm"},{"fact_type":"executive_change","fact_key":"60eaa0536c","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-10-02T23:59:59+00:00","payload":{"action":"relinquished responsibilities","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-10-01","interim":true,"role":"principal financial officer (interim)","role_category":"cfo","successor_name":"Michael Shankman","successor_named":true},"claim":"Richard Christopher changed role as principal financial officer (interim) at Lexaria Bioscience Corp..","evidence_excerpt":"Richard Christopher, the Company’s Chief Executive Officer who assumed the responsibilities as the Company’s principal financial officer on an interim basis, relinquished those responsibilities to Mr. Shankman.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001640334-24-001473","anchor_url":"https://secwatch.observer/filing/0001640334-24-001473#claim-60eaa0536c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001473/0001640334-24-001473-index.htm"},{"fact_type":"executive_change","fact_key":"074b8353a8","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-10-02T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-15","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Michael Shankman","successor_named":true},"claim":"Nelson Cabatuan resigned as Chief Financial Officer at Lexaria Bioscience Corp..","evidence_excerpt":"replacing Lexaria’s former CFO, Nelson Cabatuan who resigned effective July 15, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-24-001473","anchor_url":"https://secwatch.observer/filing/0001640334-24-001473#claim-074b8353a8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001473/0001640334-24-001473-index.htm"},{"fact_type":"executive_change","fact_key":"ac77ddb58c","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-10-02T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Michael Shankman was appointed as Chief Financial Officer at Lexaria Bioscience Corp..","evidence_excerpt":"Effective October 1, 2024, Michael Shankman, age 64, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-24-001473","anchor_url":"https://secwatch.observer/filing/0001640334-24-001473#claim-ac77ddb58c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001473/0001640334-24-001473-index.htm"},{"fact_type":"executive_change","fact_key":"17f47d9cf5","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-09-05T23:59:59+00:00","payload":{"action":null,"action_category":"role_change","departure_tone":"routine","effective_date":"2024-08-31","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":"Richard Christopher","successor_named":true},"claim":"Christopher Bunka changed role as Chairman of the Board at Lexaria Bioscience Corp..","evidence_excerpt":"replacing Christopher Bunka who will remain as the Company’s Chairman of the Board and as a strategic advisor","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-24-001396","anchor_url":"https://secwatch.observer/filing/0001640334-24-001396#claim-17f47d9cf5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001396/0001640334-24-001396-index.htm"},{"fact_type":"executive_change","fact_key":"0bfe18faf0","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-09-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-31","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Richard Christopher was appointed as Chief Executive Officer at Lexaria Bioscience Corp..","evidence_excerpt":"appointed Richard Christopher, age 54, to the position of Chief Executive Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-24-001396","anchor_url":"https://secwatch.observer/filing/0001640334-24-001396#claim-0bfe18faf0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001396/0001640334-24-001396-index.htm"},{"fact_type":"executive_change","fact_key":"c97ef11b1a","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-07-17T23:59:59+00:00","payload":{"action":"resigned","action_category":"role_change","departure_tone":"routine","effective_date":"2024-07-15","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Nelson Cabatuan resigned as Chief Financial Officer at Lexaria Bioscience Corp..","evidence_excerpt":"Effective on July 15, 2024, Mr. Nelson Cabatuan resigned from his position as the Company’s Chief Financial Officer in order to focus his attention on corporate finance and strategic industry relationships for Lexaria as its Chief Strategic Financial Advisor.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001640334-24-001132","anchor_url":"https://secwatch.observer/filing/0001640334-24-001132#claim-c97ef11b1a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001132/0001640334-24-001132-index.htm"},{"fact_type":"material_agreement","fact_key":"56c226db48010cc15fddb4da3944999697594e5c","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-04-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Warrant Exercise Agreement","agreement_type":"equity_purchase","counterparty":"an existing accredited investor","effective_date":"2024-04-30","item_codes_triggered":["1.01"],"value_text":"approximately $4.7 million"},"claim":"Lexaria Bioscience Corp. entered into Warrant Exercise Agreement with an existing accredited investor valued at approximately $4.7 million (effective 2024-04-30).","evidence_excerpt":"On April 30, 2024, Lexaria Bioscience Corp. (the “Company”) entered into a warrant exercise agreement (the “Warrant Exercise Agreement”) with an existing accredited investor (the “Investor”) to exercise in full an outstanding Common Stock Purchase Warrant (the “Exercise”) to purchase up to an aggregate of 2,917,032 shares of the Company’s common stock (the “Existing Warrant”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-24-000708","anchor_url":"https://secwatch.observer/filing/0001640334-24-000708#claim-56c226db48010cc15fddb4da3944999697594e5c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000708/0001640334-24-000708-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e2c362f79e9e13470fdd41b806c4bab344ae46d8","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-04-24T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-23","outcome":"passed","proposal_text":"To Ratify the lawful actions of the directors for the past year","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"2,432,746","subject":null,"votes_abstain":"54,505","votes_against":"67,011","votes_for":"4,110,965","votes_withheld":null}]},"claim":"Lexaria Bioscience Corp. shareholders approved To Ratify the lawful actions of the directors for the past year at the 2024-04-23 meeting.","evidence_excerpt":"To Ratify the lawful actions of the directors for the past year 4,110,965 67,011 54,505 2,432,746 97 %","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-24-000702","anchor_url":"https://secwatch.observer/filing/0001640334-24-000702#claim-e2c362f79e9e13470fdd41b806c4bab344ae46d8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000702/0001640334-24-000702-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4a8c03de7640d2a3950cda0f53439c083ba4de1e","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-04-24T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-23","outcome":"passed","proposal_text":"To Appoint Malone Bailey LLP as Auditors","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"39,529","votes_against":"59,519","votes_for":"6,566,179","votes_withheld":null}]},"claim":"Lexaria Bioscience Corp. shareholders approved To Appoint Malone Bailey LLP as Auditors at the 2024-04-23 meeting.","evidence_excerpt":"To Appoint Malone Bailey LLP as Auditors 6,566,179 59,519 39,529 0 99 %","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-24-000702","anchor_url":"https://secwatch.observer/filing/0001640334-24-000702#claim-4a8c03de7640d2a3950cda0f53439c083ba4de1e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000702/0001640334-24-000702-index.htm"},{"fact_type":"shareholder_vote","fact_key":"aafd1ddbed4ca334c512449b312ab9fbe45e7a72","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-04-24T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-23","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"2,432,746","subject":"Chris Bunka","votes_abstain":null,"votes_against":"43,840","votes_for":"4,188,641","votes_withheld":null},{"broker_non_votes":"2,432,746","subject":"John Docherty","votes_abstain":null,"votes_against":"42,904","votes_for":"4,189,577","votes_withheld":null},{"broker_non_votes":"2,432,746","subject":"Nicholas Baxter","votes_abstain":null,"votes_against":"71,287","votes_for":"4,161,194","votes_withheld":null},{"broker_non_votes":"2,432,746","subject":"Ted McKechnie","votes_abstain":null,"votes_against":"496,623","votes_for":"3,735,858","votes_withheld":null},{"broker_non_votes":"2,432,746","subject":"Albert Reese Jr.","votes_abstain":null,"votes_against":"629,452","votes_for":"3,603,029","votes_withheld":null},{"broker_non_votes":"2,432,746","subject":"Dr. Catherine Turkel","votes_abstain":null,"votes_against":"50,698","votes_for":"4,181,783","votes_withheld":null}]},"claim":"Lexaria Bioscience Corp. shareholders approved Election of Directors at the 2024-04-23 meeting.","evidence_excerpt":"To Elect Chris Bunka as a director 4,188,641 43,840 N/A 2,432,746 99 % To Elect John Docherty as a director 4,189,577 42,904 N/A 2,432,746 99 % To Elect Nicholas Baxter as a director 4,161,194 71,287 N/A 2,432,746 98 % To Elect Ted McKechnie as a director 3,735,858 496,623 N/A 2,432,746 88 % To Elect Albert Reese Jr. as a director 3,603,029 629,452 N/A 2,432,746 85 % To Elect Dr. Catherine Turkel as a director 4,181,783 50,698 N/A 2,432,746 99 %","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-24-000702","anchor_url":"https://secwatch.observer/filing/0001640334-24-000702#claim-aafd1ddbed4ca334c512449b312ab9fbe45e7a72","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000702/0001640334-24-000702-index.htm"},{"fact_type":"executive_change","fact_key":"140190acf5","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-03-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-14","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Nelson Cabatuan was appointed as Chief Financial Officer at Lexaria Bioscience Corp..","evidence_excerpt":"Effective March 14, 2024, Nelson Cabatuan, age 46, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-24-000410","anchor_url":"https://secwatch.observer/filing/0001640334-24-000410#claim-140190acf5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000410/0001640334-24-000410-index.htm"},{"fact_type":"material_agreement","fact_key":"13b3d3f8d381c54e430c5d636420e2bab99db095","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-02-16T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Engagement Agreement","agreement_type":"underwriting","counterparty":"H.C. Wainwright & Co., LLC","effective_date":"2024-02-12","item_codes_triggered":["1.01"],"value_text":null},"claim":"Lexaria Bioscience Corp. entered into Engagement Agreement with H.C. Wainwright & Co., LLC (effective 2024-02-12).","evidence_excerpt":"In connection with the Offering, on February 12, 2024, the Company entered into an engagement agreement (the “Engagement Agreement”) with H.C. Wainwright & Co., LLC (the “Placement Agent”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-24-000271","anchor_url":"https://secwatch.observer/filing/0001640334-24-000271#claim-13b3d3f8d381c54e430c5d636420e2bab99db095","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000271/0001640334-24-000271-index.htm"},{"fact_type":"material_agreement","fact_key":"c3fd95bc5a1fbcdfcd5001afdf44d5febaf2e80b","cik":1348362,"ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-02-16T23:59:59+00:00","payload":{"action":"entry","agreement_name":"securities purchase agreement","agreement_type":"equity_purchase","counterparty":"certain institutional investors","effective_date":"2024-02-14","item_codes_triggered":["1.01"],"value_text":"approximately $3.6 million"},"claim":"Lexaria Bioscience Corp. entered into securities purchase agreement with certain institutional investors valued at approximately $3.6 million (effective 2024-02-14).","evidence_excerpt":"On February 14, 2024, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with certain institutional investors","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-24-000271","anchor_url":"https://secwatch.observer/filing/0001640334-24-000271#claim-c3fd95bc5a1fbcdfcd5001afdf44d5febaf2e80b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000271/0001640334-24-000271-index.htm"}]}